ENTX

Entera Bio Ltd. [ENTX] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

ENTX Stock Summary

The Moving Average Convergence Divergence (MACD) for ENTX recently turned positive (within last 10 days).

Top 10 Correlated ETFs

ENTX

Top 10 Correlated Stocks

ENTX

In the News

ENTX Financial details

Company Rating

Market Cap

105.73M

Income

-4.47M

Revenue

Book val./share

Cash/share

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

03 May 2024

P/E

-3.85

Forward P/E

PEG

0.58

P/S

1564.19

P/B

3.51

P/C

P/FCF

-3.26

Quick Ratio

3.74

Current Ratio

3.95

Debt / Equity

LT Debt / Equity

EPS (TTM)

-0.15

EPS next Y

EPS next Q

EPS this Y

-31.11%

EPS next Y

EPS next 5Y

EPS last 5Y

-19.2%

Revenue last 5Y

-100%

Revenue Q/Q

EPS Q/Q

-18.64%

SMA20

17.78%

SMA50

-10.92%

SMA100

28.48%

Inst Own

Inst Trans

ROA

-66%

ROE

-63%

ROC

-0.85%

Gross Margin

-15757%

Oper. Margin

-39800%

Profit Margin

-40629%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

0.52-3.35

52W High

52W Low

RSI

60.93

Rel Volume

0.35

Avg Volume

182.6K

Volume

64.34K

Perf Week

17.93%

Perf Month

11.28%

Perf Quarter

21.91%

Perf Half Y

16.67%

Beta

1.713

Volatility

0.14%, 0.22%

Prev Close

-2.69%

Price

2.17

Change

-4.82%

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 182.6K
Market Capitalization 105.73M
Employee 17
CEO Ms. Miranda J. Toledano M.B.A.
Headquarters Jerusalem,IL
IPO Date 2018-06-28
Website https://www.enterabio.com

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.